While the SAVOR-TIMI-53 clinical trial showed increased heart failure hospitalizations, this finding has not been redemonstrated in other clinical studies, and a recent study from Japan showed better long-term outcomes in heart failure patients treated with DPP-4 inhibitors [11–13]. The gene discussed is DPP4; the disease is heart failure.